Cancer Stem Cell News Volume 4.08 | Mar 4 2015


    Cancer Stem Cell News 4.08 March 4, 2015

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

    Growth Signal Can Influence Cancer Cells’ Vulnerability to Drugs, Study Suggests
    Researchers report one culprit that fuels variable vulnerability within squamous cell cancers: exposure to a signal known as TGF-β, given off by immune cells that congregate next to a tumor’s blood vessels.[Press Release from the Rockefeller University discussing online publication in Cell]
    Press Release | Abstract | Graphical Abstract
    View Webinar: Genome Editing: From Modeling Disease to Novel Therapeutics

    PUBLICATIONS (Ranked by impact factor of the journal)
    The LIM-Only Transcription Factor LMO2 Determines Tumorigenic and Angiogenic Traits in Glioma Stem Cells
    The authors investigated the oncogenic roles of Lim domain only 2 (LMO2) in glioblastoma and glioma stem cells (GSCs) in mice and human. High expression of LMO2 was found in human patient-derived GSCs compared with the differentiated progeny cells. [Cell Death Differ] Abstract

    Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanism
    The authors studied in vitro and in vivo, the effects of CD47 inhibition on cancer stem cells (CSCs) using a large set of primary pancreatic cancer (stem) cells as well as xenografts of primary human pancreatic ductal adenocarcinoma tissue. [Clin Cancer Res] Abstract

    Extracellular Vesicles in the Biology of Brain Tumour Stem Cells – Implications for Inter-Cellular Communication, Therapy and Biomarker Development
    Glioma stem cells may carry signatures of either proneural or mesenchymal glioblastoma (GBM) subtypes and differ in several biological characteristics that are, at least in part, represented by the output and repertoire of extracellular vesicleproduction (vesiculome). Researchers report that vesiculomes differ between known GBM subtypes [Semin Cell Dev Biol] Abstract

    Vemurafenib Resistance Selects for Highly Malignant Brain and Lung-Metastasizing Melanoma Cells
    Researchers identified possible biomarkers associated with the emergence of drug resistant melanoma cells. Resistant cells expressed higher levels of genes coding for cancer stem cell markers, as well as genes involved in drug resistance, cell invasion and promotion of metastasis. [Cancer Lett] Abstract

    Sonic Hedgehog (Shh) Signaling Promotes Tumorigenicity and Stemness via Activation of Epithelial-to-Mesenchymal Transition (EMT) in Bladder Cancer
    Investigators show a role for Shh signaling in the promotion of epithelial-to-mesenchymal transition, tumorigenicity, and stemness in the bladder cancer. The bladder cancer specific stem cell markers CK5 and CK14 were upregulated in the TGF-β1 treated xenograft tumor samples, while CD44 remained unchanged in both treated and untreated tumors. [Mol Carcinog] Abstract

    VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients
    A subpopulation of cancer stem cells (CSCs) of ovarian carcinoma was isolated and the genes differentially expressed in these cells were identified to characterize CSCs, and to find candidate biomarkers. [Stem Cells Dev] Abstract

    Dormancy Activation Mechanism of Oral Cavity Cancer Stem Cells
    Understanding the mechanisms by which cancer stem cells are maintained in the dormant G0 phase, and how they become active is key to developing new cancer therapies. Scientists found that the anti-cancer drug 5-fluorouracil, acting on the oral squamous cell carcinoma KB cell line, selectively killed proliferating cells while sparing cells in the G0 phase. [Tumor Biol] Abstract

    Wnt Signaling Regulates the Stemness of Lung Cancer Stem Cells and Its Inhibitors Exert Anticancer Effect on Lung Cancer SPC-A1 Cells
    The authors explored the role of Wnt signaling in the lung cancer stem cells (LCSCs). They showed that LCSCs were successfully generated as they expressed pluripotent stem cell markers Nanog and Oct 4, and lung distal epithelial markers CCSP and SP-C, by which the phenotype characterization of stem cells can be confirmed. [Med Oncol] Abstract

    Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium

    Cellular Immunotherapy in Ovarian Cancer: Targeting the Stem of Recurrence
    The authors review the available data on the immune contexture surrounding ovarian cancer and discuss novel strategies and targets for immunotherapy in ovarian cancer. In the end the addition of immunotherapy to existing therapeutic options could lead to a great improvement in the outcome of ovarian cancer, especially when targeting cancer stem cells. [Gynecol Oncol] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    NYU Langone Medical Center and the Technion-Israel Institute of Technology to Forge Groundbreaking Partnership in Cancer Research
    NYU Langone Medical Center and the Technion-Israel Institute of Technology announced a $9 million gift from philanthropists Laura and Isaac Perlmutter that will fund two major, joint research endeavors with potentially far-reaching impact in advancing cancer research. [NYU Langone Medical Center] Press Release

    Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center’s Clinical Research Division
    Cryoport, Inc. announced the expansion of its relationship with Fred Hutchinson Cancer Research Centers’ Clinical Research Division with the inclusion of additional labs to be supported by Cryoport’s validated cryogenic logistics solutions for its cell-based therapies. [Cryoport, Inc.] Press Release

    US Studies Confirm Ability of TRXE-009 to Kill Brain Cancer Stem Cells
    Novogen Limited announced that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [Novogen Limited] Press Release

    Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer
    Oncolytics Biotech® Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead product candidate, REOLYSIN®, for the treatment of primary peritoneal cancers. [Oncolytics Biotech® Inc.] Press Release

    Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube
    Oncolytics Biotech® Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead product candidate, REOLYSIN®, for the treatment of cancer of the fallopian tube. [Oncolytics Biotech® Inc.] Press Release

    New wallchart from our sponsor:
    Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
    Request your free copy.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW American Association for Cancer Research (AACR) Annual Meeting 2015
    April 18-22, 2015
    Philadelphia, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW PhD Positions – Immunological Aspects of Cancer and Allergy (University of Salzburg)

    NEW Postdoctoral Positions – Stem Cell and Cancer (Brigham & Women’s Hospital)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Postdoctoral Position – Stem Cell Biology & Cancer Biology (Oregon Health and Science University)

    Research Technician II – Pediatric Cancer and Stem Cells (Massachusetts General Hospital)

    Director – Vector Production (Sangamo BioSciences, Inc.)

    Senior Process Development Engineer (Sangamo BioSciences, Inc.)

    Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

    Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us